Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2018
At a glance
- Drugs APVO 210 (Primary)
- Indications Psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Aptevo Therapeutics
- 06 Dec 2018 Status changed from planning to not yet recruiting.
- 01 Dec 2018 New trial record
- 14 Nov 2018 According to an Aptevo Therapeutics media release, company plans to initiate this study in the first quarter of 2019.